AETHLON MEDICAL INC Form 8-K May 31, 2011

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 26, 2011

#### AETHLON MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Nevada 000-21846 13-3632859

(State or other jurisdiction of Commission File Number)

(I.R.S. Employer Identification No.)

incorporation)

8910 University Center Lane, Suite 660

San Diego, California (Address of principal executive offices)

92122 (Zip Code)

Registrant's telephone number, including area code: (858) 459-7800

#### Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

## Item 7.01 Regulation FD Disclosure

The Registrant disclosed that on Thursday, May 26, 2011, it made a presentation at the C21 BioVentures Drug Partnering Conference in Napa, California. A copy of the investor presentation materials are being furnished as an exhibit to this report and are incorporated by reference into this Item 7.01. Also, the Registrant posted the investor presentation materials to its website (www.aethlonmedical.com) today, May 31, 2011.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits. The following exhibit is being furnished pursuant to Item 7.01 above.

Exhibit No. Description

99.1 Aethlon C21 Presentation 05-26-11

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AETHLON MEDICAL, INC. (Registrant)

Date: May 31, 2011 By: /s/ James B. Frakes

James B. Frakes

Chief Financial Officer

# EXHIBIT INDEX

Exhibit No. Description

99.1 Presentation Materials